PHARVARIS NV (PHVS)
NL00150005Y4 - Common Stock
Bullish Two Hundred Day Moving Average Cross - PHVS
PHVS Stock Earnings: Pharvaris Misses EPS for Q4 2023
PHVS stock results show that Pharvaris missed analyst estimates for earnings per share the fourth quarter of 2023.
PHVS Stock Earnings: Pharvaris Misses EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pharvaris (NASDAQ:PHVS) just reported results for the fourth quarter of 2023.Ph...
Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
RAPIDe-3, a global pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, is currently enrollingEnd-of-Phase 2 meeting...
Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer
Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer
ZUG, Switzerland, April 10, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin...
Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference
Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference
ZUG, Switzerland, April 04, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin...
Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses
The company announced the initiation of RAPIDe-3, the Phase 3 clinical trial evaluating the efficacy and safety of deucrictibant immediate-release capsule...
Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses
Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses
ZUG, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor...
Pharvaris to Participate in the Leerink Global Biopharma Conference 2024
Pharvaris to Participate in the Leerink Global Biopharma Conference 2024
ZUG, Switzerland, March 05, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor...
Pharvaris Enters Oversold Territory (PHVS)
Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting
Antagonism of the bradykinin B2 receptor via treatment with deucrictibant resulted in statistically significant reduction in rate of HAE attacks
Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting
Antagonism of the bradykinin B2 receptor via treatment with deucrictibant resulted in statistically significant reduction in rate of HAE attacks...
Pharvaris Announces Extraordinary Meeting of Shareholders
Pharvaris Announces Extraordinary Meeting of Shareholders
ZUG, Switzerland , Feb. 16, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor...
Pharvaris to Present at the WSAAI Annual Meeting 2024
Pharvaris to Present at the WSAAI Annual Meeting 2024
ZUG, Switzerland, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor...
Top-Notch Pharvaris Eyes Profit-Taking Zone On A Key FDA Decision
The company is working on a treatment for swelling attacks associated with a genetic disease.
Pharvaris rises as FDA lifts hold on hereditary angioedema candidate (NASDAQ:PHVS)
Shares of Swiss biotech Pharvaris (PHVS) rise as U.S. regulators lift clinical hold on testing for its proposed treatment for hereditary angioedema (HAE).
Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks
Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks
ZUG, Switzerland, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor...
Pharvaris Provides Business Update and Outlines 2024 Strategic Priorities
Pharvaris Provides Business Update and Outlines 2024 Strategic Priorities
RAPIDe-3, a global Phase 3 clinical study of deucrictibant for the on-demand treatment of HAE, to initiate within 1H24Results of nonclinical rodent...
Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023
ZUG, Switzerland, Dec. 08, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor...
AMD Stock Alert: What to Expect From Advanced Micro Devices ‘Advancing AI’ Event
Advanced Micro Devices stock is climbing higher on Wednesday as AMD investors prepare for the company's Advancing AI event today.
Shopify (SHOP) Stock Falls Following Analyst Downgrade
Shopify stock is taking a beating on Wednesday after shares of SHOP were hit with a downgrade from Wedbush analyst Scott Devitt.
Why Is Pharvaris (PHVS) Stock Up 36% Today?
Pharvaris stock is rising higher on Wednesday following news of an underwritten offering for PHVS shares and pre-funded warrants.